Press Releases

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Nov 16, 2022
WATERTOWN, Mass. , Nov. 16, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that the Company granted
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Nov 07, 2022
WATERTOWN, Mass. , Nov. 07, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that EyePoint Pharmaceuticals will
EyePoint Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Developments
Nov 02, 2022
– Initiated Phase 2 DAVIO 2 clinical trial for wet age-related macular degeneration (wet AMD) and Phase 2 PAVIA clinical trial for non-proliferative diabetic retinopathy (NPDR) – – Presented positive twelve-month safety and efficacy data from Phase 1 DAVIO clinical trial for EYP-1901 in wet AMD at
EyePoint Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 2, 2022
Oct 26, 2022
WATERTOWN, Mass. , Oct. 26, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Oct 17, 2022
WATERTOWN, Mass. , Oct. 17, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that the Company granted
EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 PAVIA Clinical Trial of EYP-1901 for the Treatment of Non-Proliferative Diabetic Retinopathy
Sep 29, 2022
WATERTOWN, Mass. , Sept. 29, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that the first patient has been dosed
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Sep 16, 2022
WATERTOWN, Mass. , Sept. 16, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that the Company granted
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Sep 06, 2022
WATERTOWN, Mass. , Sept. 06, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that EyePoint Pharmaceuticals will
EyePoint Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Developments
Aug 03, 2022
– First patient dosed in the Phase 2 DAVIO 2 clinical trial for wet age-related macular degeneration (wet AMD) – – Presented positive twelve-month safety and efficacy data from Phase 1 DAVIO clinical trial for EYP-1901 in wet AMD at American Society of Retina Specialists (ASRS) 2022 Annual Meeting
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
Aug 02, 2022
WATERTOWN, Mass. , Aug. 02, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that EyePoint Pharmaceuticals’ will
EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Maintenance Treatment of Wet AMD
Aug 01, 2022
-Topline data expected in the second half of 2023- WATERTOWN, Mass. , Aug. 1, 2022 /PRNewswire/ -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today
EyePoint Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022
Jul 27, 2022
WATERTOWN, Mass. , July 27, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call and live
EyePoint Pharmaceuticals Investor Day to Highlight EYP-1901 and Durasert® Technology Developments and Provide a Financial Update
Jul 18, 2022
- Positive 12-Month Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD announced at ASRS 2022 Annual Meeting - Phase 2 clinical trial (DAVIO 2) in wet AMD and in non-proliferative diabetic retinopathy (NPDR) patient dosing anticipated in Q3
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jul 18, 2022
WATERTOWN, Mass. , July 18, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that the Company granted
EyePoint Pharmaceuticals Announces Positive 12-Month Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD
Jul 15, 2022
Data reinforces strong safety and efficacy for EYP-1901 as a potential six-month maintenance treatment for previously treated wet AMD No dose limiting toxicities, no ocular serious adverse events (SAEs) and no drug-related systemic SAEs observed Stable visual acuity and optical coherence tomography
EyePoint Pharmaceuticals to Host Investor Day on July 18, 2022
Jul 11, 2022
- Guest speakers Carl Regillo , M.D., FACS, Professor of Ophthalmology, Thomas Jefferson University and Charles C. Wykoff , M.D., Ph.D., Director of Research, Retina Consultants of Texas - WATERTOWN, Mass. , July 11, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc.
EyePoint Pharmaceuticals Appoints Karen Zaderej to Board of Directors
Jul 11, 2022
WATERTOWN, Mass. , July 11, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced the appointment of Karen Zaderej to its
EyePoint Pharmaceuticals Announces Election of Tony Adamis, M.D. to Board of Directors
Jun 23, 2022
WATERTOWN, Mass. , June 23, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced the election of Anthony (Tony) Adamis ,
EyePoint Pharmaceuticals and OcuMension Therapeutics Announce Approval of New Drug Application by China’s NMPA for YUTIQ® for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
Jun 21, 2022
WATERTOWN, Mass. and BEIJING , June 21, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, and OcuMension Therapeutics (HKSE:
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Jun 16, 2022
WATERTOWN, Mass. , June 16, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that the Company granted
Displaying 1 - 20 of 465